Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17373875 | 1.00 | MAPT (0.34) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17373888 | 0.89 | KMT2A (0.35) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17373886 | 0.89 | KMT2A (0.35) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17373883 | 0.86 | ALDH1A1 (0.34) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17373880 | 0.86 | ALDH1A1 (0.34) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL18207832 | 0.85 | KMT2A (0.35) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL18207831 | 0.85 | KMT2A (0.35) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17373816 | 0.84 | GPR119 (0.31) | GPR119 | |
| SCHEMBL17373815 | 0.84 | GPR119 (0.31) | GPR119 | |
| SCHEMBL17373952 | 0.80 | MEN1 (0.36) | MAPTALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | MAPT 1391/4885ALDH1A1 1980/4885GAA 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.